GeneDx Holdings Financials

WGS Stock   99.13  3.28  3.42%   
Based on the key indicators related to GeneDx Holdings' liquidity, profitability, solvency, and operating efficiency, GeneDx Holdings Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, GeneDx Holdings' Short and Long Term Debt Total is comparatively stable compared to the past year. Cash is likely to gain to about 130.8 M in 2025, whereas Accounts Payable is likely to drop slightly above 7.6 M in 2025. Key indicators impacting GeneDx Holdings' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio2.463.6114
Way Down
Slightly volatile
Investors should never underestimate GeneDx Holdings' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor GeneDx Holdings' cash flow, debt, and profitability to make informed and accurate decisions about investing in GeneDx Holdings Corp.

Net Income

(54.9 Million)

  
Understanding current and past GeneDx Holdings Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GeneDx Holdings' financial statements are interrelated, with each one affecting the others. For example, an increase in GeneDx Holdings' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in GeneDx Holdings' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GeneDx Holdings Corp. Check GeneDx Holdings' Beneish M Score to see the likelihood of GeneDx Holdings' management manipulating its earnings.

GeneDx Holdings Stock Summary

GeneDx Holdings competes with Privia Health, HealthStream, Certara, National Research, and Definitive Healthcare. GeneDx Holdings is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS81663L2007
CUSIP81663L200 81663L101 18978W109
LocationConnecticut; U.S.A
Business AddressNorth Tower, Stamford,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.genedx.com
Phone888 729 1206

GeneDx Holdings Key Financial Ratios

GeneDx Holdings Key Balance Sheet Accounts

202020212022202320242025 (projected)
Other Current Liab39.6M56.1M87.4M44.4M43.5M50.3M
Retained Earnings(330.1M)(575.4M)(1.1B)(1.3B)(1.4B)(1.3B)
Accounts Payable26.7M44.7M46.0M10.2M8.0M7.6M
Other Assets14.4M7.8M7.4M1.00.90.86
Net Receivables32.3M26.6M43.3M32.8M37.6M35.6M
Inventory25.0M33.5M13.7M8.8M10.7M14.3M
Other Current Assets8.7M23.0M18.2M10.6M8.5M12.8M
Total Current Assets174.1M483.5M212.6M182.3M198.0M188.6M

GeneDx Holdings Key Income Statement Accounts

The reason investors look at the income statement is to determine what GeneDx Holdings' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Net Interest Income(2.0M)(2.8M)(666K)1.1M(3.0M)(2.9M)
Interest Expense2.5M2.8M3.2M3.0M3.5M2.7M
Total Revenue179.3M212.2M234.7M202.6M305.5M243.9M
Gross Profit4.0M(16.6M)(26.8M)60.6M194.4M204.1M
Operating Income(242.0M)(446.1M)(667.7M)(163.7M)(23.2M)(24.4M)
Ebit(238.9M)(242.6M)(461.2M)(170.2M)(153.2M)(160.8M)
Research Development72.7M105.2M86.2M58.3M45.7M53.7M
Ebitda(224.7M)(219.2M)(398.2M)(136.5M)(23.2M)(24.4M)
Cost Of Revenue175.3M228.8M261.4M141.9M111.1M137.6M
Income Before Tax(241.3M)(245.4M)(598.0M)(176.7M)(52.6M)(55.3M)
Net Income(246.4M)(245.4M)(549.0M)(175.8M)(52.3M)(54.9M)
Income Tax Expense5.1M21.6M(49.1M)(926K)(343K)(360.2K)

GeneDx Holdings Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(9.0M)(10.6M)4.6M975K(2.6M)(2.7M)
Investments(32.0M)(20.8M)(141.3M)(41.7M)(30.1M)(31.6M)
Change In Cash4.0M282.5M(263.2M)(37.7M)(14.5M)(13.7M)
Free Cash Flow(125.1M)(211.2M)(333.5M)(185.9M)(34.0M)(35.7M)
Depreciation11.7M21.8M59.3M35.8M22.0M28.8M
Other Non Cash Items2.4M1.6M141.5M(721K)(7.0M)(6.6M)
Capital Expenditures32.0M20.8M14.3M5.7M5.5M5.2M
Net Income(241.3M)(245.4M)(549.0M)(175.8M)(52.3M)(54.9M)
End Period Cash Flow119.0M401.5M138.3M99.7M86.2M127.9M

GeneDx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining GeneDx Holdings's current stock value. Our valuation model uses many indicators to compare GeneDx Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GeneDx Holdings competition to find correlations between indicators driving GeneDx Holdings's intrinsic value. More Info.
GeneDx Holdings Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, GeneDx Holdings' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value GeneDx Holdings by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

GeneDx Holdings Corp Systematic Risk

GeneDx Holdings' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GeneDx Holdings volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on GeneDx Holdings Corp correlated with the market. If Beta is less than 0 GeneDx Holdings generally moves in the opposite direction as compared to the market. If GeneDx Holdings Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GeneDx Holdings Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GeneDx Holdings is generally in the same direction as the market. If Beta > 1 GeneDx Holdings moves generally in the same direction as, but more than the movement of the benchmark.

GeneDx Holdings Thematic Clasifications

GeneDx Holdings Corp is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
HealthcareView
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in GeneDx Holdings Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GeneDx Holdings' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of GeneDx Holdings growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.57

At this time, GeneDx Holdings' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

GeneDx Holdings February 27, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of GeneDx Holdings help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GeneDx Holdings Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of GeneDx Holdings Corp based on widely used predictive technical indicators. In general, we focus on analyzing GeneDx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GeneDx Holdings's daily price indicators and compare them against related drivers.

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.